NEW YORK (GenomeWeb) – Veracyte late on Wednesday priced its previously announced public offering of 5 million shares of its common stock at $10.25 per share to raise an anticipated $51.3 million in gross proceeds.
The South San Francisco, California-based developer of genomics-based diagnostics expects the offering to close on or about July 30 and has granted its underwriters a 30-day option to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions.
Leerink Partners and William Blair are the joint book-running managers for the offering. BTIG is the lead manager.
Veracyte said proceeds will go toward working capital and other general corporate purposes. It may also use proceeds to acquire or invest in complementary businesses, technologies, or other assets.
The firm currently offers diagnostic tests for thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. This week its CEO Bonnie Anderson discussed the company’s plans in the pharmaceutical space and said that its growing database of transcriptome data could drive future deals with biopharmaceutical companies interested in developing precision medicine therapies.
The company also reported a 24 percent year-over-year increase in its Q2 revenues.